Drs. Neil Iyengar and Kelly McCann review the phase III DESTINY-Breast11 trial, highlighting its design, patient population, and key findings demonstrating improved pathologic complete response rates with a trastuzumab deruxtecan–based neoadjuvant regimen in high-risk HER2-positive early breast cancer.
Dr. Neil Iyengar moderates a discussion with Dr. Alison Conlin and Dr. Kelly McCann on the design of the DESTINY-Breast11 trial and its implications for the management of HER2-positive early breast cancer.
Dr. Neil Iyengar continues the discussion on HER2-positive early breast cancer by exploring how the DESTINY-Breast11 findings may translate into routine clinical practice.
Dr. Neil Iyengar shifts the discussion to the management of residual disease in HER2-positive early breast cancer, inviting Dr. Alison Conlin to review the phase III DESTINY-Breast05 trial.
Dr. Neil Iyengar shifts the discussion to the management of residual disease in HER2-positive early breast cancer, inviting Dr. Alison Conlin to review the phase III DESTINY-Breast05 trial.
Dr. Neil Iyengar leads a discussion with Dr. Kelly McCann and Dr. Alison Conlin on balancing efficacy with safety when incorporating newer therapies into the management of HER2-positive early breast cancer.
Dr. Neil Iyengar presents a clinical scenario involving a patient with high-risk HER2-positive early breast cancer, prompting Dr. Kelly McCann and Dr. Alison Conlin to discuss practical treatment selection in the neoadjuvant setting.
Dr. Neil Iyengar presents a second clinical scenario focused on a patient with residual invasive disease following neoadjuvant therapy for HER2-positive early breast cancer, prompting Dr. Alison Conlin and Dr. Kelly McCann to discuss adjuvant treatment decision-making.
Dr. Neil Iyengar concludes the case-based discussion by exploring the role of multidisciplinary care in the management of HER2-positive early breast cancer following neoadjuvant therapy.
In the closing segment, Dr. Neil Iyengar invites Dr. Kelly McCann and Dr. Alison Conlin to reflect on how emerging evidence is shaping the future management of HER2-positive early breast cancer.
